Business Context and Reporting Period
This Form 8-K was filed by aTyr Pharma, Inc. on October 28, 2015. The report discloses a change in the Company's executive leadership regarding its principal accounting officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Appointment of Principal Accounting Officer: The Board of Directors appointed Mr. John T. Blake as the Company's principal accounting officer, effective immediately.
- Promotion: Mr. Blake was promoted to Vice President, Finance.
- Transition of Duties: Mr. Blake succeeds Mr. Stan Blackburn in the role of principal accounting officer.
- Continued Role: Mr. Blackburn will continue to serve as the Company's Acting Chief Financial Officer, principal financial officer, and financial consultant.
Management Commentary and Background
Mr. Blake, 39, has served as the Senior Director Finance and Controller since March 2015. Prior to joining aTyr Pharma, he held senior finance roles at Volcano Corporation and Entropic Communications. He is a Certified Public Accountant (CPA) with a Bachelor of Business Administration from National University. The Company confirmed there are no undisclosed understandings regarding his appointment and no material interests in Company transactions.
Investor Verification Checklist
- Verify the effective date of Mr. Blake's appointment as principal accounting officer (October 28, 2015).
- Confirm Mr. Stan Blackburn's continued status as Acting CFO and financial consultant.
- Review Mr. Blake's professional background, specifically his tenure as Controller since March 2015.
- Check for any subsequent filings regarding the permanent appointment of a Chief Financial Officer.